Health Care Equipment

MP CARDIOFLOW-B

MP CARDIOFLOW-B released FY2025 Q3 earnings on March 30 (BJT), actual revenue HKD 96.75 M, actual EPS HKD -0.1389

MP CARDIOFLOW-B released FY2025 9 Months Earnings on March 30, 2026 (BJT) with actual revenue of HKD 344.81 M and EPS of HKD -0.1439

MP CARDIOFLOW-B released FY2025 earnings on March 30 After-Market (BJT), actual revenue HKD 444.81 M (forecast HKD 539.58 M), actual EPS HKD -0.2981 (forecast HKD -0.0361)

MP CARDIOFLOW-B released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue HKD 94.48 M, actual EPS HKD -0.1388

MP CARDIOFLOW-B to Release FY2025 Earnings on March 30 After-Market (BJT), Forecast Revenue HKD 549.18 M, EPS HKD -0.0368

Microport Cardiovascular's New ICD Included in NMPA Special Review Program

MicroPort CardioFlow-B shareholders deposit shares with Standard Chartered (Hong Kong), company plans to merge shares

MicroPort CardioFlow-B Shareholders Deposit Shares with Yunfeng Securities and Announce AltaValveTM One-Year Follow-Up Results

Hearthware Completes the Issuance of About 3.954 Billion New Shares

Hearmed-B Establishes Strategy and Commercialization Committees and Adjusts Board Members

Shentong Medical Plans to Fully Acquire MicroPort CRM, Expanding Business Scope to a Comprehensive Platform Covering Structural Heart Disease, Cardiac Rhythm Management and Heart Failure Management

MP CARDIOFLOW-B released FY2025 Q1 earnings on August 28, 2025 (BJT) with actual revenue of HKD 122.68 M and EPS of HKD -0.0024

MP CARDIOFLOW-B released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), with actual revenue of HKD 248.06 M and EPS of HKD -0.005

MP CARDIOFLOW-B released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue HKD 125.38 M, actual EPS HKD -0.0025

CARDIOFLOW-B to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Cordance Medical-B Anticipates a Net Loss Reduction of No Less Than 83% in H1 2025

Chang Zhaohua Suggests Merging MicroPort's Cardiac Rhythm Management Business with HeartFlow Medical

MicroPort Plans to Merge Cardiac Rhythm Management Business into MicroPort Medical

Change of Independent Non-Executive Director at China Medical Technologies-B

Full Acquisition of Shanghai ZuoXin's Remaining 49% Shares by Vessel Medical's Fully-Owned Subsidiary

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02160

MicroPort CardioFlow Medtech Corp. has scheduled its annual general meeting for June 4, 2026, in Shanghai. Shareholders will review the company's financial statements and consider resolutions to authorize a share buyback of up to 10% of issued capital and the issuance of additional shares. These measures aim to enhance capital management and support future financing activities, potentially benefiting shareholder returns. MicroPort CardioFlow specializes in cardiovascular treatments and is listed on the Hong Kong Stock Exchange with a market cap of HK$3.02B.

Tip Ranks

MicroPort CardioFlow Sets 2026 AGM, Seeks Fresh Share Buyback and Issuance Mandates

02635

02565

06656

02556

02465

09993

02442

09678

02591

NUOBIKAN(02635) fell 33.69%, with a trading turnover 322.5 Million HKD, and a year-to-date rose 21.4%. PEGBIO CO-B(02565) fell 13.79%, with a trading turnover 24.9 Million HKD, and a year-to-date fell 47.8%. SIGENERGY(06656) fell 9.37%, with a trading turnover 587.7 Million HKD, and a year-to-date rose 67%.

Top Gainers&Losers

NUOBIKAN

PEGBIO CO-B

SIGENERGY

MARKETINGFORCE

LOPAL TECH

RADIANCE HLDGS

EASY SMART GP

UNISOUND

INNOGEN-B

Top 10 HK Stock Losers (4.21)

MicroPort CardioFlow Medtech Corp. (HK:2160) has announced new international distribution agreements with its major shareholder, MicroPort, to distribute cardiovascular and electrophysiology products in select overseas regions, including Europe. These agreements, effective until the end of 2028, are classified as continuing connected transactions under Hong Kong listing rules, exempting the company from independent shareholder approval. The latest analyst rating for HK:2160 is a Sell with a price target of HK$0.74, and the company has a market cap of HK$3.69B.

MicroPort CardioFlow Expands Overseas Distribution Via New Connected Deals

688351

00853

02172

02252

159883

562600

159898

688016

Bank of America Securities has lowered the target price for MICROPORT to 13.9 yuan, reiterating a "Buy" rating. It expects total revenue in 2025 to be USD 1.105 billion, with a year-on-year increase of 6% after excluding foreign exchange factors. Its "GloMatrix" platform has achieved breakeven, and revenue for the fiscal year 2025 is expected to grow by 78.8% to 163.9 million yuan. Due to the exclusion of MICROPORT NEURO from the consolidated financial statements, revenue forecasts for 2026 to 2028 have been reduced by 10.9% to 12.9%. At the same time, gross margin forecasts have been raised by 1.9 to 2.1 percentage points, and operating expense ratio forecasts have been raised by 11.5 to 12.6 percentage points

AASTOCKS

MICROPORT EP

MICROPORT

MICROPORT NEURO

MircroPort Medbot-B

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Endovastec

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

MicroPort announced its 2025 annual performance, with revenue of USD 1.105 billion, an increase of 7.2% year-on-year; gross profit of USD 635 million, an increase of 10.5%. It recorded a net profit of USD 48.52 million, compared to a loss of USD 214 million in the previous year, turning a loss into a profit; earnings per share of 2.59 cents. No final dividend will be distributed

"Performance" MICROPORT achieved a net profit of USD 48.52 million for the entire year, turning a loss into a profit

06636

02629

06090

03881

00568

02068

02291

09903

02276

EXTREME VISION(06636) fell 28%, with a trading turnover 236.3 Million HKD, and a year-to-date rose 80%. MIRXES-B(02629) fell 20.24%, with a trading turnover 800.0 Million HKD, and a year-to-date fell 71.8%. BUTONG GROUP(06090) fell 20.01%, with a trading turnover 63.6 Million HKD, and a year-to-date fell 59.2%.

EXTREME VISION

MIRXES-B

BUTONG GROUP

CIDI

SHANDONG MOLONG

CHALIECO

SCIENTECH

ILUVATAR COREX

CONANT OPTICAL

Top 10 HK Stock Losers (3.31)

MP CARDIOFLOW-B announced its 2025 annual performance, with revenue recorded at USD 57.04 million, an increase of 12.3% year-on-year. The loss expanded from USD 6.95 million in the previous year to USD 18.82 million, with a loss per share of 4 cents. No final dividend will be distributed

"Performance" MP CARDIOFLOW-B's annual loss expands to 18.82 million USD

MicroPort CardioFlow Medtech Corp. has announced a change in its reporting currency from Renminbi to U.S. dollars to align with its globalization strategy and the contribution of its subsidiary, MicroPort Cardiac Rhythm Management Limited. This change aims to provide clearer financial performance insights for shareholders and investors, with prior-year figures restated in USD starting with the 2025 annual report. The current analyst rating for the stock (HK:2160) is a Hold, with a price target of HK$0.76.

MicroPort CardioFlow Switches Reporting Currency to U.S. Dollars

MP CARDIOFLOW-B(02160.HK)